md-medicaldata

Authors

 

Zorana Kozić¹, Bojana Cikota-Aleksić¹, Olivera Tarabar², Dragana Stamatović², Zvonko Magić<sup>1

1</sup>Institute of medical research and /Institut za medicinska istraživanja i
²Clinic for hematology, Military Medical Academy, Belgrade, Serbia / Klinika za hematologiju, Vojnomedicinske Akademije

 

Rad je primljen 14.11.2017. / Prihvaćen 16.11.2017.

 

Correspondence to

Dr Zorana Kozić spec.biol.,
Vojnomedicinska akademija,
Beograd, Srbija
Crnotravska 17
e-mail: zinzoran@gmail.com

 

 

Abstract

 

Modern treatment protocols for acute lymphoblastic leukemia (ALL) include the analysis of minimal residual disease (MRD), the detection of small number of malignant cells that survived after therapy. MRD diagnostics represents the most sensitive method to evaluate treatment response and the strongest prognostic factor in ALL patients. Detection of MRD is commonly based on polymerase chain reaction (PCR) analysis of rearranged immunoglobuline heavy chain (IGH) or T-cell receptor (TCR) genes in bone marrow (BM) samples. Since BM sampling is invasive and traumatic, the aim of this study was to evaluate clinical usefulness of MRD monitoring in the peripheral blood (PB). The study included 59 patients with ALL (44 B-ALL and 15 T- ALL). Samples of PB and BM were taken after induction therapy and during the follow-up. Clonality testing was based on PCR analyses of rearranged IGH or TCR gamma genes. In patients with B-ALL, MRD was detected in BM of 10 patients and in PB of 6 patients. In T-ALL, MRD was detected in BM of 7 patients and in PB of 6 patients. Obtained results indicated that in patients with B-ALL MRD assessment of BM is more informative than analysis of PB, while in T-ALL traumatic BM sampling might be replaced with PB.

 

 

 

Key words:

minimal residual disease (MRD), acute lymphoblastic leukemia (ALL), bone marrow (BM)

 

 

Sažetak

 

Savremeni protokoli za lečenje akutne limfoblastne leukemije (ALL) uključuju analizu minimalne rezidualne bolesti (MRD), otkrivanje malih količina malignih ćelija koje su preživele posle terapije. MRD dijagnostika predstavlja najosetljiviji metod za procenu odgovora na lečenje i najjači prognostički faktor kod ALL bolesnika. Detekcija MRD-a se najčešće zasniva na PCR analizi rearanžmana gena imunoglobulinskog teškog lanca (IGH) ili T-ćelijskog receptora (TCR) u uzorcima kostne srži (BM). Budući da je uzorkovanje BM invazivno i traumatično, cilj ove studije bio je procena kliničke korisnosti MRD monitoringa u perifernoj krvi (PB). Studija je obuhvatila 59 pacijenata sa ALL (44 B-ALL i 15 T-ALL). Uzorci PB i BM su uzeti nakon indukcione terapije i tokom praćenja. Testiranje klonalnosti je zasnovano na PCR analizama rearanžiranih IGH ili TCR gama gena. Kod pacijenata sa B-ALL, MRD je detektovana u BM kod 10 pacijenata i u PB kod 6 pacijenata. Kod T-ALL, MRD je detektovana u BM kod 7 pacijenata, a u PB kod 6 pacijenata. Dobijeni rezultati pokazuju da je kod pacijenata sa B-ALL procena MRD u BM više informativna nego analiza PB, dok se kod T-ALL traumatično uzorkovanje iz BM može zameniti analizom PB.

 

 

Ključne reči:

minimalna rezidualna bolest (MRD), akutna limfoblastna leukemija (ALL), kostna srž (BM)

 

 

References

 

1. Onciu M. Acute Lymphoblastic Leukemia. Hematol.Oncol.Clin.N Am. 2009; 23: 655-674
2. Pui CH, Robison L, Look AT. Acute lymphoblastic leukemia. Lancet . 2008; 371:1030-4
3. Brüggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012; 120(23):4470-4481 
4. Parikh SK, Uparkar UP. Assessment of minimal residual disease in childhood acute lymphoblastic leukemia. J Appl Hematol. 2016;7:47-53   
5. Campana D, Pui CH. Detectuon of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995; 85: 1416-1434
6. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR; principles, approaches, and laboratory aspects. Leukemia. 2003; 17:1013-34
7. van Dongen JJ, van der Velden VH, Brüggemann M and Orfao A Minimal residual disease diagnostics in acute lymphoblasic leukemia: need for sensitive, fast and standardized technologies. Blood. 2015; 125: 3996-4009
8. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangments: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007; 26:604-611
9. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet. 1998; 352(9142):1731-1738
10. Coustan-Smith E, Sancho J, Hancock LM, et al. Use of peripheral blood insted of  bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002;100:2399-2402
11. Greaves MF. Differentiantion-linked leukemogenesis in lymphocytes. Science 1986;234:697-704
12. Harris NL, Jaffe ES, Diebold J, et al. 1999 World Health Organisacion clasification of neoplastic diesese of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849
13. Cikota MB, Tukić JLJ, Tarabar TO, Stamatović TD Elez NM, Magić MZ. PCR-based clonality assessment in patients with lymphocytic leukemias: a single-institution experience. J Genet. 2009;88:309-314
14. Paietta E. Assessening minimal residual disease (MRD) in leukemia: a changing definition and concept? Bone Marrow Transplantation. 2002; 29(6):459-456
15. van der Velden VH, Jacobs DC,Wijkhuijs AJ et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia. 2002; 16(8): 1432-1436.
16. Volejnikova J, Mejstrikova E, Valova T, Reznickova L, Hodonska L, et al. Minimal residual disease in pripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis. Haematologica. 2011; 96(12):1815-1821
17. van der Velden VH, de Bie M, van Wering ER, van Dongen JJ. Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia:characteristics and applicability for detection on minimal residual disease. Haematologica. 2006; 91(5): 679-682

UDK: 616.155.392-07
616.419-07

PDF Kozić Z. et al • MD-Medical Data 2017;9(4): 219-222